MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
14.33
-0.13
-0.90%
After Hours: 14.31 -0.02 -0.14% 16:08 02/03 EST
OPEN
14.26
PREV CLOSE
14.46
HIGH
14.63
LOW
14.25
VOLUME
648.08K
TURNOVER
0
52 WEEK HIGH
29.62
52 WEEK LOW
6.91
MARKET CAP
705.01M
P/E (TTM)
-5.3709
1D
5D
1M
3M
1Y
5Y
JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
TipRanks · 01/25 15:55
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
Seeking Alpha · 01/11 18:59
Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 323.4% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revision...
Zacks · 12/05/2022 14:55
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors ...
PR Newswire · 12/01/2022 12:05
Protagonist Therapeutics Reports Granting of Inducement Award
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2022, it issued inducement awards to Arturo Molina, M.D., M.S., F.A.C.P., the Company's recently hired Chief Medical Officer, in accordance with the terms of Dr. Molina's empl...
PR Newswire · 11/16/2022 21:05
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337%
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 337.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does in...
Zacks · 11/11/2022 14:55
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Lowers Price Target to $33
Benzinga · 11/10/2022 12:15
--HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
--HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT Newswires · 11/10/2022 09:54
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s alpha-4-beta-7 (α4β7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted α4β7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.

Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.